跳至主要内容
临床试验/ISRCTN12628444
ISRCTN12628444进行中(未招募)未知

Development of a program for early diagnosis and treatment of cardiotoxic complications caused by chemotherapy for breast cancer (PREDICATE)

Ministry of Education and Science of the Republic of Kazakhstan0 个研究点目标入组 120 人开始时间: 2022年7月21日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
120

研究概览

简要总结

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36359556/ (added 10/11/2023) 2021 Results article in https://doi.org/10.23950/jcmk/11412 patients' survival and their cardiovascular system condition (added 10/11/2023) 2023 Results article in https://doi.org/10.23950/jcmk/13325 stratifying patients based on cancer treatment-related cardiovascular disease (added 10/11/2023) 2023 Results article in https://doi.org/10.3390/diagnostics13233557 Role of Clinical Risk Factors and B-Type Natriuretic Peptide in Assessing the Risk of Asymptomatic Cardiotoxicity in Breast Cancer Patients in Kazakhstan (added 04/12/2023)

研究设计

研究类型
Observational

入排标准

性别
Female

入选标准

  • 1. Verified diagnosis of C50 malignant neoplasm of the breast at any stage (if eligible for chemotherapy), according to the Republican Protocol for Diagnosis and Treatment of Breast Cancer dated March 01, 2019, No. 56, upon admittance to the University's Medical Center
  • 2. Any age
  • 3. Out/inpatient treatment in the Medical Center
  • 4. Targeted therapy upon the confirmed positive Her2 status and/or Anthracyclines administering
  • 5. Simpson left ventricular ejection fraction =40% without symptoms of heart failure established within 30 days before admission to the chemotherapy division

排除标准

  • Current participant exclusion criteria as of 29/07/2022:
  • 1. Coronary heart disease (CHD) progression or congestive heart failure (CHF) decompensation
  • 2. Simpson left ventricular ejection fraction =40%
  • 3. Any recurrent comorbid pathology decompensation
  • Previous participant exclusion criteria:
  • 1. Presence of recorded cardiotoxic effects of chemotherapy, regardless of the limitation period
  • 2. Coronary heart disease (CHD) progression or congestive heart failure (CHF) decompensation in the previous six months
  • 3. Simpson left ventricular ejection fraction =40%;
  • 4. Decompensation of comorbid pathology within the previous three months:
  • 4.1. Endocrine diseases
  • 4.2. Diseases of the liver
  • 4.3. Diseases of the kidneys
  • 4.4. Diseases of the bronchopulmonary system

研究者

发起方
Ministry of Education and Science of the Republic of Kazakhstan

相似试验